Health
Idorsia’s daridorexant in women during menopausal transition age with insomnia
New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition ageBrigham and Women’s Hospital to study the effectiveness and safety of daridorexant for menopause-related insomnia symptoms Allschwil, Switzerland – January 5, 2026Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal transition
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition age","length":170,"tagName":"p"}]},{"val":[{"type":"text","content":"Brigham and Women’s Hospital to study the effectiveness and safety of daridorexant for menopause-related insomnia symptoms","length":122,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":292,"olType":false},{"type":"text","content":"Allschwil, Switzerland – January 5, 2026Idorsia Ltd (SIX: IDIA) announces the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal transition age: Insights from a randomized controlled trial” in Maturitas, a prestigious international journal of midlife health and beyond. This new analysis of the efficacy and safety of daridorexant in women aged 47–55 years with insomnia disorder – a population representative of the menopausal transition – is based on data from the Phase 3 randomized controlled trial (NCT03545191) published in Lancet Neurology and provides important insights into the management of insomnia during in midlife women.","length":703,"tagName":"p"},{"type":"text","content":"One of the most prevalent and burdensome yet under-researched symptoms reported by women in the menopausal transition is sleep disturbance1,2. Multiple factors, including hormonal changes, vasomotor symptoms (e.g. hot flushes, night sweats), psychological changes (e.g. mood symptoms, depression), development of other sleep disorders (e.g. restless legs syndrome, obstructive sleep apnea), and social demands (e.g. caregiving), may contribute, either triggering the onset of or exacerbating preexisting sleep disturbances3. Sleep disturbances can have ...